Biblio
Export 1335 results:
Author Title Type [ Year] Filters: First Letter Of Last Name is P [Clear All Filters]
“Normal Pressure Hydrocephalus in Down Syndrome: The Report of Two Cases.”, J Alzheimers Dis, vol. 77, no. 3, pp. 979-984, 2020.
, “Odor Identification Impairment and Change with Cholinesterase Inhibitor Treatment in Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 75, no. 3, pp. 845-854, 2020.
, “Partial Inhibition of Mitochondrial Complex I Reduces Tau Pathology and Improves Energy Homeostasis and Synaptic Function in 3xTg-AD Mice.”, J Alzheimers Dis, vol. 79, no. 1, pp. 335-353, 2020.
, “Plasma High Density Lipoprotein Small Subclass is Reduced in Alzheimer's Disease Patients and Correlates with Cognitive Performance.”, J Alzheimers Dis, vol. 77, no. 2, pp. 733-744, 2020.
, “Potential Novel Role of COVID-19 in Alzheimer's Disease and Preventative Mitigation Strategies.”, J Alzheimers Dis, vol. 76, no. 1, pp. 21-25, 2020.
, “Reduced Hippocampal Glutamate and Posterior Cingulate N-Acetyl Aspartate in Mild Cognitive Impairment and Alzheimer's Disease Is Associated with Episodic Memory Performance and White Matter Integrity in the Cingulum: A Pilot Study.”, J Alzheimers Dis, vol. 73, no. 4, pp. 1385-1405, 2020.
, “Revised Framingham Stroke Risk Profile: Association with Cognitive Status and MRI-Derived Volumetric Measures.”, J Alzheimers Dis, vol. 78, no. 4, pp. 1393-1408, 2020.
, “Revised Framingham Stroke Risk Profile: Association with Cognitive Status and MRI-Derived Volumetric Measures.”, J Alzheimers Dis, vol. 78, no. 4, pp. 1393-1408, 2020.
, “Revised Framingham Stroke Risk Profile: Association with Cognitive Status and MRI-Derived Volumetric Measures.”, J Alzheimers Dis, vol. 78, no. 4, pp. 1393-1408, 2020.
, “Revised Framingham Stroke Risk Profile: Association with Cognitive Status and MRI-Derived Volumetric Measures.”, J Alzheimers Dis, vol. 78, no. 4, pp. 1393-1408, 2020.
, “Serum Hepcidin Levels in Cognitively Normal Older Adults with High Neocortical Amyloid-β Load.”, J Alzheimers Dis, vol. 76, no. 1, pp. 291-301, 2020.
, “Sleep-Wake Cycle in Alzheimer's Disease Is Associated with Tau Pathology and Orexin Dysregulation.”, J Alzheimers Dis, vol. 74, no. 2, pp. 501-508, 2020.
, “Soluble TREM2 and Inflammatory Proteins in Alzheimer's Disease Cerebrospinal Fluid.”, J Alzheimers Dis, vol. 73, no. 4, pp. 1615-1626, 2020.
, “Structural Brain Changes in Pre-Clinical FTD MAPT Mutation Carriers.”, J Alzheimers Dis, vol. 75, no. 2, pp. 595-606, 2020.
, “Structural Brain Magnetic Resonance Imaging to Rule Out Comorbid Pathology in the Assessment of Alzheimer's Disease Dementia: Findings from the Ontario Neurodegenerative Disease Research Initiative (ONDRI) Study and Clinical Trials Over the Past 10 Years.”, J Alzheimers Dis, vol. 74, no. 3, pp. 747-757, 2020.
, “Structural Brain Magnetic Resonance Imaging to Rule Out Comorbid Pathology in the Assessment of Alzheimer's Disease Dementia: Findings from the Ontario Neurodegenerative Disease Research Initiative (ONDRI) Study and Clinical Trials Over the Past 10 Years.”, J Alzheimers Dis, vol. 74, no. 3, pp. 747-757, 2020.
, “Ultra-High Field MRI in Alzheimer's Disease: Effective Transverse Relaxation Rate and Quantitative Susceptibility Mapping of Human Brain In Vivo and Ex Vivo Compared to Histology.”, J Alzheimers Dis, vol. 73, no. 4, pp. 1481-1499, 2020.
, “Ultra-High Field MRI in Alzheimer's Disease: Effective Transverse Relaxation Rate and Quantitative Susceptibility Mapping of Human Brain In Vivo and Ex Vivo Compared to Histology.”, J Alzheimers Dis, vol. 73, no. 4, pp. 1481-1499, 2020.
, “Use of Immersive Virtual Reality in the Assessment and Treatment of Alzheimer's Disease: A Systematic Review.”, J Alzheimers Dis, vol. 75, no. 1, pp. 23-43, 2020.
, “Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimer's Disease Multimodal Biomarker Discovery Cohort.”, J Alzheimers Dis, vol. 74, no. 1, pp. 213-225, 2020.
, “Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimer's Disease Multimodal Biomarker Discovery Cohort.”, J Alzheimers Dis, vol. 74, no. 1, pp. 213-225, 2020.
, “18F-FDG Is a Superior Indicator of Cognitive Performance Compared to 18F-Florbetapir in Alzheimer's Disease and Mild Cognitive Impairment Evaluation: A Global Quantitative Analysis.”, J Alzheimers Dis, vol. 70, no. 4, pp. 1197-1207, 2019.
, “Adverse Vascular Risk Relates to Cerebrospinal Fluid Biomarker Evidence of Axonal Injury in the Presence of Alzheimer's Disease Pathology.”, J Alzheimers Dis, vol. 71, no. 1, pp. 281-290, 2019.
, “Air Pollution and Dementia: A Systematic Review.”, J Alzheimers Dis, vol. 70, no. s1, pp. S145-S163, 2019.
, “Air Pollution and Dementia: A Systematic Review.”, J Alzheimers Dis, vol. 70, no. s1, pp. S145-S163, 2019.
,